评估候选结核病疫苗方案ChAdOx1 85A初免-MVA85A加强在健康英国成人中的安全性和免疫原性的I期试验
该I期试验在42名已接种卡介苗的健康英国成人中评估ChAdOx1 85A初免-MVA85A加强方案的安全性及免疫原性。不良事件多为轻中度,无严重不良事件;ChAdOx1 85A诱导抗原特异性ELISpot及CD4+、CD8+ T细胞应答,第二剂ChAdOx1 85A未加强应答,但MVA85A可加强。结论为该方案耐受良好且具免疫原性。
要点
- 不良事件多为轻中度,未报告严重不良事件。
- ChAdOx1 85A诱导的T细胞应答未被第二剂ChAdOx1 85A加强,但被MVA85A加强。
- ChAdOx1 85A诱导的血清Ag85A IgG应答被MVA85A加强。
核心结论
- ChAdOx1 85A初免-MVA85A加强方案在健康英国成人中耐受良好且具免疫原性。
研究设计与样本
- I期试验纳入42名已接种卡介苗的健康英国成人,分为低剂量起始组(n=6,单用ChAdOx1 85A)、A组(n=12,ChAdOx1 85A)、B组(n=12,ChAdOx1 85A初免-MVA85A加强)和C组(n=12,ChAdOx1 85A-ChAdOx1 85A初免-MVA85A加强)。
- 安全性通过收集征集性和非征集性疫苗相关不良事件评估,免疫原性通过抗原特异性离体IFN-γ ELISpot、IgG血清ELISA及抗原特异性细胞内IFN-γ、TNF-α、IL-2和IL-17检测。
主要发现
- 不良事件多为轻中度,未报告严重不良事件。
- ChAdOx1 85A诱导Ag85A特异性ELISpot及细胞内细胞因子CD4+和CD8+ T细胞应答,第二剂ChAdOx1 85A未加强该应答,但MVA85A可加强。
- ChAdOx1 85A诱导多功能CD4+ T细胞(IFN-γ、TNF-α和IL-2)及IFN-γ+、TNF-α+ CD8+ T细胞,并被MVA85A加强。
- ChAdOx1 85A诱导血清Ag85A IgG应答,并被MVA85A加强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This phase I trial evaluated the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost, previously demonstrated to be protective in animal studies, in healthy UK adults. METHODS: We enrolled 42 healthy, BCG-vaccinated adults into 4 groups: low dose Starter Group (n = 6; ChAdOx1 85A alone), high dose groups; Group A (n = 12; ChAdOx1 85A), Group B (n = 12; ChAdOx1 85A prime - MVA85A boost) or Group C (n = 12; ChAdOx1 85A - ChAdOx1 85A prime - MVA85A boost). Safety was determined by collection of solicited and unsolicited vaccine-related adverse events (AEs). Immunogenicity was measured by antigen-specific ex-vivo IFN-γ ELISpot, IgG serum ELISA, and antigen-specific intracellular IFN-γ, TNF-α, IL-2 and IL-17. RESULTS: AEs were mostly mild/moderate, with no Serious Adverse Events. ChAdOx1 85A induced Ag85A-specific ELISpot and intracellular cytokine CD4+ and CD8+ T cell responses, which were not boosted by a second dose, but were boosted with MVA85A. Polyfunctional CD4+ T cells (IFN-γ, TNF-α and IL-2) and IFN-γ+, TNF-α+ CD8+ T cells were induced by ChAdOx1 85A and boosted by MVA85A. ChAdOx1 85A induced serum Ag85A IgG responses which were boosted by MVA85A. CONCLUSION: A ChAdOx1 85A prime - MVA85A boost is well tolerated and immunogenic in healthy UK adults.
引用
- Wilkie M, Satti I, Minhinnick A, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults. Vaccine. 2019. PMID: 31735500. doi:10.1016/j.vaccine.2019.10.102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。